2020
DOI: 10.3390/ijms21197424
|View full text |Cite
|
Sign up to set email alerts
|

T Cell Activation Machinery: Form and Function in Natural and Engineered Immune Receptors

Abstract: The impressive success of chimeric antigen receptor (CAR)-T cell therapies in treating advanced B-cell malignancies has spurred a frenzy of activity aimed at developing CAR-T therapies for other cancers, particularly solid tumors, and optimizing engineered T cells for maximum clinical benefit in many different disease contexts. A rapidly growing body of design work is examining every modular component of traditional single-chain CARs as well as expanding out into many new and innovative engineered immunorecept… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
5
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
8

Relationship

2
6

Authors

Journals

citations
Cited by 9 publications
(5 citation statements)
references
References 186 publications
(269 reference statements)
0
5
0
Order By: Relevance
“…For example, in CD28, the dimerization potential of the YxxxxT motif was reported to be comparable to that of glycophorin A’s GxxxG motif ( 34 , 54 , 55 ), the most common benchmark in TM helix dimerization. This has immediate clinical implications, because CD28 TM domains are used in chimeric antigen receptors (CARs) for cancer immunotherapy ( 56 , 57 ), where the YxxxxT motif drives unintended interactions between CARs and endogenous CD28 in patient T cells ( 35 , 58 ) and may thereby contribute to enhanced function ( 59 ) and/or toxicity ( 57 ).…”
Section: Discussionmentioning
confidence: 99%
“…For example, in CD28, the dimerization potential of the YxxxxT motif was reported to be comparable to that of glycophorin A’s GxxxG motif ( 34 , 54 , 55 ), the most common benchmark in TM helix dimerization. This has immediate clinical implications, because CD28 TM domains are used in chimeric antigen receptors (CARs) for cancer immunotherapy ( 56 , 57 ), where the YxxxxT motif drives unintended interactions between CARs and endogenous CD28 in patient T cells ( 35 , 58 ) and may thereby contribute to enhanced function ( 59 ) and/or toxicity ( 57 ).…”
Section: Discussionmentioning
confidence: 99%
“…T cells amplified and activated in vitro, including cytokine-induced killer cells (CIK), TIL, and tumor antigen-specific CTL, can also be adopted into the tumor-bearing host. The most important achievement in this regard has been modified T cells based on chimeric antigen receptor (CAR) (CAR-T) [ 130 ]. In CAR T cell therapy, genetically engineered autologous T cells expressing CAR are used in patients.…”
Section: Immunotherapy Of Hncs Associated With T Cellsmentioning
confidence: 99%
“…However, a tight regulation of the immune response is essential to preserve the integrity of the organisms. Thus, T-cells suffering immunosenescent modifications 14 , chemotactic expansion, or exhaustion in response to physiological aging 15 , constant TCR triggering, costimulatory/inhibitory factors 16 can actually be responsible of immune dysregulation and contribute to different pathologies including a wide-variety of neoplasms 17 .…”
Section: Highlightsmentioning
confidence: 99%